An optimized 3-step strategy for preventing and treating post-operation relapse and metastasis of malignant tumors with traditional Chinese medicine

Journal of Chinese Integrative Medicine

Volumn 5, Issue 1, 2007, Pages 5-10

  Xu, Zhen Ye ^a   Zheng, Zhan ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Metastasis; Relapse; Traditional Chinese medicine; Tumors

Indexed keywords

ALCOHOL; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHEMOEMBOLIZATION; CHINESE MEDICINE; HUMAN; LIVER CANCER; LIVER SURGERY; LUNG CANCER; LUNG SURGERY; METASTASIS; POSTOPERATIVE CARE; PRIMARY PREVENTION; PROCESS OPTIMIZATION; STOMACH CANCER; STOMACH SURGERY;

EID: 33846477791     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20070102     Document Type: Article

References (36)

1. Tang ZY. Modern oncology. 2nd ed. Shanghai: Shanghai Medical University Press. 2000: 254. Chinese.
2. Xu ZY, Yang YF. Comprehensive treatment of lung cancer with traditional Chinese and Western medicine. Beijing: Peoples Medical Publishing House. 2002: 541. Chinese.
3. Tanaka F, Wada H. Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer - an evidence-based review. Gan To Kagaku Ryoho. 2006; 33(3): 300-306.
4. Uramoto H, Kagami S, Iwashige A, et al. Chemotherapy for lung cancer patients. J UOEH. 2006: 28(1): 75-84.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002; 346(2): 92-98.
6. Barlesi F, Jacot W, Astoul P, et al. Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer. 2006; 51(2): 159-172.
7. Hanna N. Advances in the treatment of second-line non-small-cell lung cancer. Lung Cancer. 2005; 50(Suppl 1): S15-S17.
8. De Marinis F, De Santis S, De Petris L. Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies. Semin Oncol. 2006; 330(1 Suppl 1): S17-24.
9. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005; 104(11): 2449-2456.
10. Dowell JE. Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact. Am J Med Sci. 2006; 331(3): 139-149.
11. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 2004; 22(5): 785-794.
12. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 2004; 22(5): 777-784.
13. Belvedere O, Grossi F. Lung Cancer Highlights from ASCO 2005. Oncologist. 2006; 11(1): 39-50.
14. Belani CP, Ramalingam S. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2005; 6(5): 267-268.
15. Tyagi P. Bevacizumab, when added to paclitaxel/carboplating prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial. Clin Lung Cancer. 2005; 6(5): 276-278.
16. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998; 27(6): 1578-1583.
17. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998; 29(1): 129-134.
18. Tang ZY. Tang Zhaoyou clinical hepatocarcinology. Shanghai: Shanghai Scientific and Technical Education Publishing House. 2001: 123. Chinese.
19. Kretzschmar A, Schlag PM. Efficacy of current adjuvant and neoadjuvant therapeutic concepts in gastric cancer? Zentralbl Chir. 2006; 131(2): 121-125.
20. Kodera Y, Fujiwara M, Koike M, et al. Chemotherapy as a component of multimodal therapy for gastric carcinoma. World J Gastroenterol. 2006; 12(13): 2000-2005.
21. Papakostas P, Tsavdaridis D, Kosmidis P, et al. Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study. Gastric Cancer. 2006; 9(1): 26-31.
22. Zhang XL, Xu SF, Xu P, et al. The study of intraperitoneal hyperthermic chemotherapy and intravenous chemotherapy after palliative operation for patients with advanced gastric carcinoma. Lin Chuang Zhong Liu Xue Za Zhi. 2006; 11(1): 43-45. Chinese with abstract in English.
23. Lin LM, Chen J, Su Y, et al. Clinical application of continuous hyperthermic peritoneal perfusion chemotherapy after operation for gastric carcinoma. Shandong Yi Yao. 2005; 45(16): 35-36. Chinese.
24. Yan GY, Xu ZY, Wang ZQ, et al. A clinical study on the synergic effect of chemotherapy combined with traditional Chinese medicine Kangliu Zengxiao Fang in treatment of advanced non-small cell lung cancer. Zhonghua Shi Yong Zhong Xi Yi Za Zhi. 2005; 18(6): 873-876. Chinese with abstract in English.
25. Zhou WD, Xu ZY, Wang ZQ, et al. Effects of "Kangliu Zengxiao Decoction" on immunological functions and serum VEGF and CYFRA21-1 in patients with non-small cell lung cancer. Shanghai Zhong Yi Yao Za Zhi. 2005; 39(3): 6-8. Chinese with abstract in English.
26. Xu ZY, Zhu YW, Zhou WD, et al. Clinical and experimental study on effect of Shuanghuang Shengbai granule on myelosuppression induced by chemotherapy and ultrastructure observation of bone marrow in mice. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001; 21(5): 328-331. Chinese with abstract in English.
27. Zhang H, Wang ZQ, Xu ZY, et al. Treatment of chemotherapy-induced myelosuppression by Shuanghuang Shengbai Granules for patients with lung cancer: analysis of 82 cases. Zhong Yi Yao Xue Kan. 2003; 21(7): 1162-1163. Chinese.
28. Wang ZQ, Xu ZY. Exploration of "qi-benefiting and essence-nourishing method" in the treatment of pulmonary cancer in middle and late stage. Shanghai Zhong Yi Yao Da Xue Xue Bao. 2002; 16(4): 30-31. Chinese with abstract in English.
29. Liu CL, Chen WP, Cui SZ, et al. Effect of Shenqi Fuzheng injection for assistance of chemotherapy in treating senile patients with non-small cell lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004; 24(10): 901-903. Chinese with abstract in English.
30. Zhao X. Clinical study of Shenqi Fuzheng Injection in relieving side reactions of radio-chemotherapy for tumor. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004: 24 (9): 857-858. Chinese.
31. Yu SZ, Yang GH, Feng JM. Clinical study on treatment of malignant neoplasms with Shenqi Fuzheng injection and chemotherapy. Zhong Xi Yi Jie He Xue Bao. 2006; 4(1): 84-86. Chinese with abstract in English.
32. Liu YX, Kuang TH, Jiang SJ. Clinical observation of cinobufacini injection in improving quality of life for patients with malignant tumor. Zhongguo Zhong Yi Yao Ke Ji. 2005; 12(1): 45-46. Chinese.
33. Chen YP, Liu XJ. Clinical observation of cinobufacini injection combined with chemotherapy in treating advanced malignant tumor. Shi Yong Zhong Xi Yi Jie He Lin Chuang. 2003; 3(2): 18. Chinese.
34. Zang AH, Rao JH, Wang ZJ, et al. The effect of Kang Lai-te injection and multimodality therapy in primary lung lancer. Zhong Liu Fang Zhi Yan Jiu. 2000; 27(4): 287-288. Chinese with abstract in English.
35. Wang YL, Li DM, Xu H, et al. Combination of Kanglaite injection and chemotherapy for treatment of advanced non-small cell lung cancer. Ai Zheng Jin Zhan Za Zhi. 2005; 3(3): 274-275. Chinese with abstract in English.
36. Zhang YP. Clinical analysis of Kanglaite injection for treatment of advanced lung cancer. Xian Dai Zhong Liu Yi Xue. 2003; 11(3): 237. Chinese.